What is the recommended prophylaxis regimen for Pneumocystis jirovecii pneumonia in patients with end‑stage renal disease, including dosing for those on dialysis and alternatives for sulfa allergy?

PJP Prophylaxis in ESRD

For patients with end-stage renal disease requiring PJP prophylaxis, use trimethoprim-sulfamethoxazole (TMP-SMX) at half the standard dose: one single-strength tablet (80 mg/400 mg) daily or one double-strength tablet three times weekly. 1

Dosing Recommendations for ESRD

First-Line: Trimethoprim-Sulfamethoxazole

For patients with creatinine clearance <15 mL/min or on dialysis:

• Prophylaxis dose: Half the usual dose (one single-strength tablet daily or one double-strength tablet 3 times weekly) 1
• Treatment dose for active PJP: 3-5 mg/kg (as trimethoprim component) every 24 hours (compared to every 6-8 hours in normal renal function) 1
• Give dose after hemodialysis on dialysis days to avoid premature drug removal 2
• Monitor CBC monthly for hematologic toxicity 3

The guideline evidence strongly supports TMP-SMX as first-line prophylaxis even in ESRD, with dose adjustment based on renal function 1. This is consistent across multiple guidelines addressing immunocompromised populations 4, 5, 6.

Alternative Agents for Sulfa Allergy

Second-Line Options:

Dapsone:

• Standard dose: 100 mg daily (maximum) 3
• Important caveat: Recent 2025 data shows once-weekly dapsone (100 mg) in kidney transplant recipients was associated with greater hemoglobin decreases and potentially increased infection risk compared to TMP-SMX 7
• Screen for G6PD deficiency before initiating
• Monitor CBC for hemolytic anemia and methemoglobinemia

Atovaquone:

• Dose: 1500 mg daily 5, 6
• No dose adjustment needed for renal impairment 1
• Better tolerated than TMP-SMX with 100% continuation rate at 1 year in some studies 8
• Major limitation: High cost and prior authorization barriers (affecting 7-8% of patients) 9
• 2012 data in renal transplant showed comparable efficacy to TMP-SMX with better tolerability 10

Aerosolized Pentamidine:

• Dose: 300 mg monthly via Respirgard II nebulizer 11, 3
• Dilute in 6 mL sterile water, deliver at 6 L/min until reservoir dry
• Pretreat with inhaled beta-2 agonist if bronchospasm occurs
• Limitation: Does not protect against extrapulmonary pneumocystosis 11
• Less commonly used due to administration complexity

Clinical Context and Risk Assessment

When to Initiate Prophylaxis in ESRD:

The original HIV guidelines established CD4+ count <200 cells/μL as the threshold 11, but for non-HIV immunocompromised patients including those with ESRD, prophylaxis indications include:

• Triple immunosuppression (corticosteroids + 2 immunomodulators, especially if one is a calcineurin inhibitor or anti-TNF) 5
• High-dose or prolonged corticosteroids plus additional immunosuppression 4
• Severe lymphopenia or hypogammaglobulinemia 4
• Post-transplant patients (particularly kidney transplant recipients with ESRD) 12, 7
• Patients receiving BCMA-targeted therapies or bispecific antibodies 4, 6

Duration of Prophylaxis:

• Kidney transplant: Varies by center from 6 months to indefinite; trend toward longer duration given late breakthrough cases 12
• During active immunosuppression: Continue throughout period of risk 4, 5
• Lung/heart transplant: Indefinite prophylaxis is standard 12

Key Pitfalls to Avoid

1. Hyperkalemia with TMP-SMX: Common in ESRD (40.9% of switches in one study) 9, but most cases resolve and patients can often resume TMP-SMX successfully (85.7% tolerance on rechallenge) 9

2. Premature discontinuation: 43% of patients discontinue TMP-SMX due to adverse events 8, but consider rechallenge after resolution rather than immediately switching to alternatives, as tolerance is high upon resumption 9

3. Underdosing in dialysis: Must give medications after dialysis to prevent removal during the session 2

4. Missing late-onset PCP: Can occur years after transplant, especially after rituximab or when prophylaxis is discontinued 13

5. Cost barriers with atovaquone: Affects 7.5% of patients and requires prior authorization in 7.8% 9

Monitoring Requirements

• CBC with differential: Monthly during TMP-SMX prophylaxis 3
• Serum potassium: More frequent monitoring in ESRD patients on TMP-SMX 1
• Serum creatinine: Baseline and periodic monitoring, though TMP-SMX increases creatinine through tubular secretion (not true GFR decline) 12

The evidence strongly supports continuing TMP-SMX as first-line even in ESRD with appropriate dose reduction, reserving alternatives primarily for true sulfa allergy or intolerable adverse effects that persist despite rechallenge. 1, 14